Conclusions
According to the results, Nrp-1 mediates TGF-β1 to improve the stability of regulatory CD4+ CD25+ T cells and maybe a possible therapeutic target with the ability to improve the CD4+ CD25+ Tregs associated negative immunoregulation that is related to the TGF-β1/Smads cell signaling during sepsis.
Methods
Spleen CD4+ CD25+ Tregs cells of mice models in the presence of LPS, were transfected with an shRNA targeting Nrp-1, Smad2, or Smad3, may or may not be treated with recombinant TGF-β1. Followed by subsequent determination of cellular proliferation, rate of apoptosis, observation of the Foxp3, CTLA-4, and TGF-β1m+ expression levels, foxp3-TSDR methylation, secretion levels of the inhibitory cytokines IL-10 and TGF-β1, and Smad2/3 of CD4+ CD25+ Tregs expression.
Results
A remarkable stimulation in CD4+ CD25+ Tregs ' stability is noted after administering recombinant TGF-β1 in the presence of LPS, and promoted cellular viability, increased Foxp3, CTLA-4, and TGF-β1m+ expression, and elevated secretion of IL-10 and TGF-β1. This also inhibited the apoptosis and methylation of foxp3- TSDR of CD4+ CD25+ Tregs . The shRNA transfection silenced Nrp-1 and Smad3, but not Smad2, resulting in the suppression of the recombinant TGF-β1-mediated effects in the presence of LPS. Conclusions: According to the results, Nrp-1 mediates TGF-β1 to improve the stability of regulatory CD4+ CD25+ T cells and maybe a possible therapeutic target with the ability to improve the CD4+ CD25+ Tregs associated negative immunoregulation that is related to the TGF-β1/Smads cell signaling during sepsis.